Effective therapies for metastatic sarcomas remain elusive. Oncolytic viruses have shown promise as anticancer agents, but their access to metastatic sites following systemic delivery is low. As systemic delivery of small-molecule chemotherapy is enhanced by previous treatment with antiangiogenic agents because of changes in intravascularto-tumor interstitial pressure, we sought to determine whether antiangiogenic pretreatment increases the antitumor efficacy of systemic virotherapy by increasing virus uptake into tumor. Virus biodistribution and antitumor effects were monitored in tumor-bearing mice given antihuman vascular endothelial growth factor (VEGF) or antimouse VEGFR2 before or after an intravenous (i.v.) injection of virus. Without pretreatment, the average virus titers in the tumor samples amplified 1700-fold over 48 h but were undetectable in other organs. After antiangiogenic treatment, average virus titers in the tumor samples were unchanged or in some cases decreased up to 100-fold. Thus, antiangiogenic pretreatment failed to improve the tumor uptake of systemic oncolytic herpes simplex virus (oHSV), in contrast to previously reported enhanced uptake of small molecules. Superior tumor control because of the combined effects of virus and anti-VEGF was seen most dramatically when anti-VEGF was given after virus. Our data suggest that i.v. oHSV can treat distant
Introduction
Advanced-stage sarcomas remain significant clinical challenges, as the use of chemotherapy has largely failed to improve the overall survival for adult patients. 1 Although there have been improvements in the survival of patients with certain localized childhood sarcomas such as rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma, 2, 3 most other sarcomas of childhood are chemoresistant. 4 For tumor types in which survival has improved with treatment, relapsed tumors are often resistant to standard therapies. In addition, therapy may be complicated in children by subsequent bone growth deformities, endocrinologic disturbances and secondary cancers. 5 Even for generally treatable sarcoma types, o30% of patients with metastatic disease survive beyond 5 years despite aggressive use of modern, combination therapies. 6 Therefore, there remains a significant need for novel sarcoma therapies to treat metastatic disease.
Oncolytic viruses are being developed as anticancer agents, either using relatively nonpathogenic virus species or using viruses attenuated by deletion of critical genes required for viral replication in normal cells but dispensable in cancer cells. 7, 8 rRp450 is an oncolytic herpes simplex virus (oHSV) derived from wild-type HSV 1, KOS strain, by replacement of the UL39 gene with rat CYP2B1 gene. 9 The UL39 gene encodes for the large subunit of ribonucleotide reductase, normally required for the virus to replicate efficiently in quiescent cells, so its deletion leads to selective viral replication in rapidly growing cancers and other dividing cells with preexisting elevated expression of cellular ribonucleotide reductase. The CYP2B1 gene encodes a cytochrome P450 enzyme that activates oxazaphosphorine prodrug chemotherapies. We have previously documented the safety and supraadditive efficacy of intratumoral rRp450 and cyclophosphamide in models of pediatric sarcomas. 10 A barrier to the use of oncolytic viruses for systemic disease is the relatively poor understanding of parameters determining the efficiency of delivery and uptake into distant tumor sites. Interstitial fluid pressure in tumors is elevated due to the leakiness of tumor vessels, [11] [12] [13] impairing the delivery of small molecules into the tumor interstitium. Jain and coworkers showed that blockade of vascular endothelial growth factor (VEGF) signaling results in maturation of tumor neovasculature and leads to a transient decrease in interstitial pressure and a pronounced intravascularinterstitial pressure gradient, peaking 2-4 days following antiangiogenic treatment. 14, 15 As predicted from these findings, previous antiangiogenic treatment has been shown to increase the systemic delivery of chemotherapeutic agents. 16 We thus hypothesized that anti-VEGF pretreatment of mice bearing sarcomas would also improve the systemic delivery of oHSV.
We studied the effect of VEGF blockade on systemically administered virus biodistribution and antitumor effects. In contrast to the findings with small-molecule therapeutics, our results suggest that antiangiogenic agents do not enhance and in some cases diminish the tumor uptake of systemically administered oHSV. We found that combination effects could be realized primarily when antiangiogenic therapy follows virus administration.
Results
Systemic delivery of oHSV to distant tumors is impaired but selectively amplified over time
We first chose a syngeneic tumor model to study virus biodistribution in order to capture any antiviral immune effects. To determine the biodistribution of systemically administered oHSV into tumors at different locations, FVBN mice were injected with syngeneic mouse rhabdomyosarcoma (MR366) cells into both subcutaneous (flank) and intramuscular (i.m.) (quadriceps) sites. When the subcutaneous tumors reached 4100 mm 3 , animals were given rRp450 intravenously (i.v.); tumors and organs were harvested at different timepoints and analyzed for the presence of virus. In previous experiments, cardiac perfusion with saline before tumor and organ harvest did not affect the levels of detectable virus (data not shown), so the contribution from intravascular virus in these experiments is considered to be minimal.
At the 1-h baseline time point, which should represent the initial uptake of virus, the amount of HSV genomes detected in the subcutaneous and i.m. tumors using quantitative polymerase chain reaction was up to 1-2 logs less than in normal organs (Figure 1a for subcutaneous and Figure 1c for i.m. tumors). The phenomenon seemed similar between these different tumor sites as well as different tumor sizes; the subcutaneous tumor weights in this experiment at the 1-h harvest were 236 ± 167 mg and the i.m. tumor weights were 2188±150 mg (tumors in the orthotopic location grow more rapidly than the subcutaneous location, although some of their higher weights may be because of nontumor tissue because they are difficult to dissect apart from normal muscle and bone). This finding is consistent with the high interstitial pressure impairing intratumoral delivery of oHSV. Detection of infectious virions was also consistent with lower initial delivery to tumor sites compared with normal organs (Figure 1b) . The amount of infectious virions recovered relative to the 10 7 plaque-forming units administered i.v. was B0.01-0.1% in organs and 0.001% in tumors. These numbers are likely quite low because the infectivity of virus is lost when it enters the cells (until a newly made infectious virus is shed). Consistent with the absence of viral replication and innate immune-mediated viral clearance from normal organs, there were no infectious viruses detected at 24 and 48 h after viral injection (Figure 1b) . In sharp contrast, there was significant virus replication in the tumors, leading to a 1700-fold increase in titer at 48 h compared with 1 h. These data correlated with the detection of HSV genomes, which amplified over time in the tumors but progressively decreased in normal organs at 24 and 48 h after virus injection ( Figure 1c ).
Antiangiogenesis fails to enhance the systemic delivery of oHSV to distant tumors
To determine the effect of antiangiogenic pretreatment on the systemic delivery of oHSV, tumor-bearing mice 
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were first given antihuman VEGF and/or antimouse VEGFR2 antibodies using both a human xenograft model and a syngeneic mouse tumor model. The A673 human xenograft model was chosen for these studies because of its known dependence on VEGF expression: it exhibits high levels of VEGF secretion relative to the other cell lines we tested (data not shown) and was the original model used in the assessment of activity of the anti-VEGF antibody, bevacizumab. 17 Nude mice harboring flank human A673 tumors were treated with the antimouse VEGFR2 antibody, DC101, bevacizumab or both, whereas FVBN mice bearing i.m. MR366 tumors were treated with the antimouse VEGFR2 antibody, DC101. Both sets of mice received rRp450 i.v. 3 days later. They were then killed at various time points and quantitative polymerase chain reaction was performed on the harvested organs.
There was no difference in the amount of HSV DNA in DC101-treated and immunoglobulin G (IgG)-treated MR366 tumors at 1, 24 and 48 h (Figure 2a ) after virus injection. In the A673 xenograft model, IgG-treated animals had 1-2 logs more virus detectable in tumors than in those harvested from animals pretreated with the antiangiogenic antibodies (P ¼ 0.09 for IgG versus DC101, P ¼ 0.014 for IgG versus bevacizumab, P ¼ 0.07 for IgG versus DC101+bevacizumab; Figure 2b ). To ensure that we did not miss the 'window' time period during which decreased interstitial pressure occurs, a cohort of A673 xenografts were given daily injections of rRp450 for 4 days, beginning 24 h following treatment with IgG or the DC101/bevacizumab combination. Again, antiangiogenic therapy did not enhance virus uptake into tumors; in fact, there was a trend for tumors from DC101/bevacizumab-treated animals to show less oHSV virus by B2 logs than those from IgG-treated animals (P ¼ 0.11, Figure 2c ).
Subsequent antiangiogenic therapy enables combined effects of antitumor efficacy with systemically administered oncolytic HSV
On the basis of our findings of decreased virus uptake following VEGF blockade in the A673 model, we postulated that a combination effect would be most evident if the virus is administered before anti-VEGF antibody. To test this hypothesis, in two independent experiments, the results of which were compiled to increase statistical power, mice bearing A673 xenografts 250-500 mm 3 were given i.v. rRp450 or intraperitoneal (i.p.) bevacizumab. After 3 days, animals were given the other treatment (i.p. bevacizumab or i.v. rRp450, respectively) and tumor sizes were monitored. Animals given either treatment alone were given the active agent (rather than the control) at the initial time point to allow for maximal effects when tumors were smallest. Animals were killed when tumors reached 42500 mm 3 or, in the first experiment, at day 34, whichever came first. The effects on tumor growth are shown in Figure 3 and those on animal survival (time to reach 2500 mm 3 ) are shown in Figure 4 . Owing to the variability in tumor growth, each individual tumor was plotted and the best response was cataloged as progressive disease (450% growth), stable disease (o50% growth or shrinkage for at least two consecutive measurements during the experiment), partial response (450% shrinkage compared with the pretreatment size), and complete response (no palpable or visible evidence of tumor). All control tumors showed rapidly progressive disease (Figure 3a) . Those given single-agent bevacizumab showed a delay in tumor 
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FK Eshun et al growth as determined by survival (see below) but little effect on response, with an overall response (stable disease+partial response+complete response) of 10% (P ¼ 0.5 versus control). Those given single-agent virus also showed a delay in growth but little effect on response, with an overall response of 22% (P ¼ 0.2 versus control). The combination with bevacizumab given first showed an increase in response compared with either agent alone, with an overall response of 40% (P ¼ 0.028 versus control), whereas the reverse order (virus first) was more dramatic, with an overall response of 75% (Po0.0002 versus control, P ¼ 0.044 versus reverse order). Significant antitumor effects were also apparent when these data were analyzed for animal survival. I.p. bevacizumab alone prolonged the survival compared with control mice given i.p. IgG, confirming the antitumor effect of anti-VEGF in this model (P ¼ 0.0002, Figure 4 ). I.v. oHSV alone also had a significant antitumor effect (P ¼ 0.0306), which was not significantly different from the effect of i.p. bevacizumab alone (P ¼ 0.8299). The addition of i.v. oHSV following i.p. bevacizumab had no additional effect on survival compared with i.p. bevacizumab alone (P ¼ 0.1239). However, when i.v. oHSV was given before i.p. bevacizumab, there was a significantly prolonged survival compared with either single agent alone (Po0.006 for both) and compared with the same combination in reverse order (P ¼ 0.0058). One mouse in the virus-only group from the second experiment (which was not arbitrarily terminated) seemed to be cured of the tumor, with no palpable mass at day 60. The marked difference in antitumor effect on the basis of sequence of administration is consistent with our finding that virus uptake in tumors is inhibited by previous VEGF blockade.
Discussion
We found that the initial delivery of systemically administered oHSV to distant tumors is impaired compared with normal organs, but that infectious virions are amplified rapidly in tumors and cleared from normal organs. Previous antiangiogenic therapy did not enhance and in some cases was detrimental to tumor uptake of systemically administered oHSV, and combination therapy was more effective than single-agent therapy only when the virus was given first.
Systemic biodistribution has been a major stumbling block for virus vectors used in gene transfer and virotherapy. The best-studied example is adenovirus, in which the 'first-pass effect' causes most particles given i.v. to be sequestered in the liver. 18 Perhaps because HSV is a larger, enveloped particle, there seems to be less of a first-pass effect, with only about one-third of detectable HSV in the liver at 12 h after administration. 19 In fact, antitumor efficacy has been shown in animal models after i.v. administered HSV mutants for subcutaneous tumors 20, 21 and pulmonary metastases, [22] [23] [24] even in the presence of neutralizing antibodies. 25 Uptake of oncolytic were given one or the other treatment or control on days 0 and 3 (arrows). Survival of animals was monitored and is shown as days after the first injection. Abbreviations: Bev, bevacizumab; PBS, phosphate-buffered saline.
VEGF blockade and systemic oncolytic HSV FK Eshun et al HSV after arterial infusion has also been shown in human trials. 26, 27 These data and studies of other viruses 28, 29 suggest that systemic i.v. virotherapy may be useful for the treatment of metastatic disease, although little is understood about the mechanisms mediating virus uptake in tumors.
Oncolytic HSV biodistribution has been examined in a genetically engineered spontaneous mouse model of prostate cancer using four virus injections over a 10-day period. HSV genomes were detected equally in prostate tumors and liver, with less in the lymph node, lung and blood. 30 There was no evidence of virus amplification in tumor sites, but virus genomes were not quantified before day 11; importantly, virus genomes persisted in the prostate tumors, whereas they were rapidly cleared from normal organs. The analyses were performed 11 days after the first virus injection and 1 day after the last, so the actual amount delivered to various sites, as opposed to that resulting from virus replication or migration, is unclear. Interestingly, oncolytic HSV given i.p. was also found in distant tumor sites and induced an antitumor effect, although full biodistribution studies were not conducted.
One limitation to systemic HSV delivery is innate immunity. After infection with most strains of wild-type HSV, mice mount vigorous innate and adaptive antiviral immune responses. HSV has evolved mechanisms such as Fc receptor binding to subvert adaptive antiviral immunity, but innate immune factors including complement have been shown in some cases to limit viral delivery to tumor sites when given regionally. [31] [32] [33] One strategy to subvert the inactivation of viruses given systemically that has been pioneered with other virus types is the use of tumor-homing cells, such as tumor cells or T cells, as delivery vehicles. 34, 35 Induction of a transient vascular leak with vasoactive agents including interleukin-2, enhanced by inhibition of Tregs, has been shown to markedly enhance the delivery of an oncolytic virus to distant tumor sites. 36 It is well documented that small-molecule drugs linked to or encapsulated in liposomes show preferential accumulation in tumors due to leaky neoangiogenic vessels (with intercellular gaps as large as 600-800 nm) and impaired lymphatic drainage, an effect known as enhanced permeability and retention. 37 A similar phenomenon for HSV uptake was not borne out by our data, as we found decreased amounts of virus within the tumor relative to other organs shortly after virus administration. It may be that compared with small-molecule drugs and their lipid conjugates, the larger size of HSV particles (B150 nm diameter) prevents passive extravasation through interendothelial cell gaps regardless of a pressure differential. In addition, there may be fewer herpesvirus receptors in tumors compared with normal organs, 38, 39 resulting in only low levels of active receptormediated uptake, which would be unaffected by pressure differentials. Whether or not tumors in different sites or organs other than the flanks and i.m. tumors tested in this study differ in this regard is unknown.
VEGF blockade has been shown to decrease tumor interstitial pressure, transiently enabling increased delivery of systemic chemotherapeutic agents to xenograft tumors before the vasculature is fully remodeled. 16, 40 In contrast, we found that VEGF blockade did not increase, and in fact in some cases decreased, the delivery of oHSV to tumor sites. The most likely explanation is the reduced tumor perfusion after antiangiogenic therapy, although we cannot rule out the formal possibility that HSV receptors were downregulated on endothelial or tumor cells by anti-VEGF antibody. This remains a possibility in light of data suggesting that VEGF upregulates HSV receptors on endothelial cells, 41 although we did not observe any effect of anti-VEGF on HSV-mediated cytotoxicity on tumor cells in culture (Supplementary Figure S1) . The effect of VEGF blockade on virus replication and spread after it has already reached the tumor is also unknown.
Anti-VEGF given after systemic oHSV administration led to better tumor control and animal survival than when given before the virus. In the latter case, there was a trend toward additive effects of combination therapy compared with bevacizumab alone (P ¼ 0.1239) but not compared with virus alone, suggesting that the lower antitumor effect of having less virus was offset by the additional antitumor effect of the bevacizumab. The reason why DC101 seemed to have less of an effect than bevacizumab is not known, but may be related to the fact that we did not optimize the doses of each antibody or to variables inherent to binding soluble ligands versus membrane-bound receptors. In addition, administration of DC101 in mice results in a compensatory increase in native systemic mouse VEGF levels, 42 which may have partially counteracted the effects of DC101. Whether such an effect occurs with bevacizumab has not been tested.
Whether or not our findings are broadly applicable to oncolytic viruses in general is not known. We did not investigate whether tumor uptake of smaller viruses, such as adenovirus or Sindbis virus, or those of a different shape (for example, filamentous), which also require receptor-mediated uptake but may better fit through endothelial gaps, is also impeded by antiangiogenic agents. Similarly, we do not yet know whether the effect will be less pronounced in other tumor models that are less dependent on VEGF. Regardless, our data suggest that tumor vascular remodeling by antiangiogenic agents fails to enhance and in some cases decreases the tumor uptake of systemically administered oncolytic HSV particles and should therefore be used after, but not before, systemic virus administration.
Materials and methods

Cells and viruses
Human Ewing's sarcoma (A673) cells were purchased from the American Type Culture Collection (Manassas, VA, USA). Mouse rhabdomyosarcoma (MR366) cells were kindly donated by Glen Merlino (NCI, Bethesda, MD, USA), after they were derived from a p53 À/À , HGFtransgenic mouse.
43 ICP6-deleted rRp450 HSV-1 (derived from strain KOS) was kindly provided by E Antonio Chiocca (Ohio State University, Columbus, OH, USA). 
In vivo studies
VEGF enzyme-linked immunosorbent assay
Athymic nude mice were treated with increasing doses of DC101. At 24 h after administration, mice were anesthetized and phlebotomy performed at the retroorbital venus plexus. Blood was collected in Microtainer plasma separating tubes (Becton Dickinson, San Jose, CA, USA) and allowed to clot at room temperature for 30 min. The clotted blood was centrifuged at 1200 g for 10 min at 4 1C. Supernatants (plasma) were collected and analyzed for mouse VEGF levels using a mouse VEGF enzyme-linked immunosorbent assay kit (R&D systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Immunodepletion was performed on samples to remove any DC101 that may be cross-reactive with the VEGF enzyme-linked immunosorbent assay kit by following the same procedure as previously described. 42 
Virus biodistribution
To determine the baseline biodistribution of systemically administered rRp450, four FVBN mice bearing both subcutaneous and i.m. MR366 tumors were given 10 7 plaque-forming units of rRp450 i.v. At various times after injection they were killed and organs and tumors were harvested ( Figure 1) . To determine the effect of antiangiogenic therapy on systemic delivery of oHSV, another group of MR366 tumor-bearing FVBN mice (n ¼ 4) were treated with i.p. injections of 40 mg per kg of DC101 (ImClone Systems, Inc., New York, NY, USA) or nonspecific rat IgG. The activity of DC101 was verified by its stimulation of plasma VEGF levels in mice as per Bocci et al. 42 (Supplementary Figure S2) . On day 3, each mouse was given 10 7 rRp450 i.v. and killed at 1, 24 and 48 h after injection (Figure 2a) . A similar experiment was performed in A673 xenografts: eight mice per group bearing A673 tumors were treated with 40 mg per kg of DC101, 10 mg per kg bevacizumab, or bevacizumab and DC101 combination, or nonspecific rat IgG i.p. On day 3 all mice were given 10 8 rRp450 i.v. and killed for organ and tumor harvest on day 6 (Figure 2b ). Three mice from the bevacizumab and four from the bevacizumab and DC101 combination group died before day 6 and were not included in the analysis. To ensure that virus was administered during the period of lowest interstitial fluid pressure, which in most tumor models has been determined to occur by day 4 after antiangiogenic therapy, 44 nude mice bearing s.c. A673 tumors (four per group) were treated with DC101/bevacizumab (40 and 10 mg per kg, respectively) or rat IgG i.p. On days 1, 2, 3 and 4 after antibody injection, each mouse was treated with 10 8 plaque-forming units rRp450 i.v. On day 5, all the mice were killed, and organs and tumors were then harvested for viral plaque assay (Figure 2c ).
Plaque assays
Harvested tumors and organs were snap-frozen in liquid nitrogen and stored at À80 1C until processed. The tumors and organs were homogenized with a Powergen tissue homogenizer (Fischer Scientific, Pittsburg, PA, USA) in 1 ml of a protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Viral plaque assays for infectious virus as well as quantitative polymerase chain reaction reactions to quantify HSV genomes were performed on the harvested organs as previously described. 10 
Antitumor efficacy
Tumor volume was determined by V ¼ (L ÂW 2 ) Â p/6, where L is the length of the tumor and W is the width. When A673 tumor volumes reached 200-250 mm 3 , mice were treated with 10 mg per kg bevacizumab i.p. or 10 8 plaque-forming units of rRp450 i.v. on day 1. On day 3 the treatments were reversed and the tumor sizes were followed. Control mice received i.p. rat IgG or i.p. bevacizumab alone. In the first experiment, when tumor volumes reached 2500 mm 3 or at day 34 (arbitrary cutoff) animals were killed. In the second experiment, animals were killed only when tumor volumes reached 2500 mm 3 . Results from the two experiments are compiled in Figures 3 and 4 (n ¼ 9-16).
Statistical analysis
Comparisons between two means were carried out with an unpaired Student's t test and more than two means by analysis of variance. Survival was analyzed by log-rank. GraphPad Prism version 5 software (GraphPad Software, San Diego, CA, USA) was used for all statistical analyses except Figure 2b , in which case we used SPSS. Owing to the variability and heteroscedacity, data were transformed to log base 10 and analyzed by the GamesHowell nonparametric post-hoc test. Tumor growth response rates in Figure 3 were analyzed by Fisher's exact test.
